Aton Ra Partners Fate Therapeutics Inc Transaction History

Aton Ra Partners

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 05, 2023	SELL	$4.24 - $11.12 $7,958 - $20,872	-1,877 Reduced 12.59%	13,035 $74,000
Q4 2022 Feb 02, 2023	SELL	$9.86 - $23.83 $39,775 - $96,130	-4,034 Reduced 21.29%	14,912 $150,000
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $11,109 - $19,039	-528 Reduced 2.71%	18,946 $425,000
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $21,744 - $51,842	-1,223 Reduced 5.91%	19,474 $483,000
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $135,265 - $274,816	4,559 Added 28.25%	20,697 $802,000
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $78,648 - $105,774	1,644 Added 11.34%	16,138 $944,000
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $516,656 - $834,478	-8,717 Reduced 37.56%	14,494 $859,000
Q2 2021 Aug 12, 2021	BUY	$67.25 - $92.52 $90,384 - $124,346	1,344 Added 6.15%	23,211 $2.01 Million
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $111,126 - $180,796	-1,540 Reduced 6.58%	21,867 $1.8 Million
Q4 2020 Feb 19, 2021	BUY	$38.09 - $100.95 $891,572 - $2.36 Million	23,407 New	23,407 $2.13 Million

177

113M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $126M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Aton Ra Partners, based on Form 13F filings with the SEC.

Stay updated on Aton Ra Partners with notifications on news.